Neuropace, Inc. NPCE Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$21.57M-0.5% | -$21.47M+10.5% | -$23.99M+7.5% | -$25.94M-4.6% | -$24.81M+8.6% | ||
| $340K+3.3% | $329K+10.8% | $297K0.0% | $297K0.0% | $297K+1.4% | ||
| $10.74M-3.1% | $11.09M0.0% | $11.09M+0.3% | $11.05M+6.6% | $10.37M+0.8% | ||
| $256K+8.0% | $237K+6.3% | $223K+11.5% | $200K+0.5% | $199K-12.7% | ||
| —— | —— | —— | —— | -$2K— | ||
| —— | —— | —— | —— | $3.8M+610% | ||
| —— | —— | $6.25M+19.2% | $5.24M+116% | $2.42M-0.2% | ||
| $499K+168% | -$730K-130% | $2.43M+3.5% | $2.35M— | —— | ||
| $1.89M-46.8% | $3.55M+58.1% | $2.25M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$553K-33.6% | -$414K-314% | -$100K+11.5% | -$113K+40.5% | -$190K+64.4% | ||
| $1.75M+2.3% | $1.71M+2.3% | $1.67M+2.3% | $1.63M+2.3% | $1.6M+2.2% | ||
| -$1.92M-3.4% | -$1.86M-3.3% | -$1.8M-3.3% | -$1.74M-3.5% | -$1.68M-3.4% | ||
| -$9.93M+13.7% | -$11.51M+29.4% | -$16.31M-1.4% | -$16.09M+10.1% | -$17.9M+0.3% | ||
| $412K+24.1% | $332K+21.2% | $274K-20.3% | $344K+43.9% | $239K-21.9% | ||
| -$412K-24.1% | -$332K-119% | $1.73M-45.3% | $3.16M-51.9% | $6.56M-27.1% | ||
| —— | —— | —— | —— | $49.55M— | ||
| $1.5M-20.0% | $1.88M+7.3% | $1.75M-1.9% | $1.78M+11.6% | $1.6M-17.4% | ||
| $491K-9.6% | $543K-0.7% | $547K-2.7% | $562K+22.2% | $460K-47.8% | ||
| —— | —— | —— | —— | $25.36M+486% | ||
| —— | —— | —— | —— | —— | ||
| $5.69M-8.1% | $6.2M-7.1% | $6.67M-6.6% | $7.14M+2.9% | $6.94M+11.5% | ||
| $256K+8.0% | $237K+6.3% | $223K+11.5% | $200K+0.5% | $199K-12.7% | ||
| $340K+3.3% | $329K+10.8% | $297K0.0% | $297K0.0% | $297K+1.4% | ||
| —— | —— | —— | —— | —— | ||
| $402K-25.3% | $538K-20.2% | $674K-16.2% | $804K-5.5% | $851K-10.8% | ||
| -$1.92M-3.4% | -$1.86M-3.3% | -$1.8M-3.3% | -$1.74M-3.5% | -$1.68M-3.4% | ||
| —— | —— | —— | —— | —— | ||
| $191K+20.1% | $159K-18.5% | $195K-23.5% | $255K+2.8% | $248K-1.2% | ||
| $1.75M+2.3% | $1.71M+2.3% | $1.67M+2.3% | $1.63M+2.3% | $1.6M+2.2% | ||
| —— | —— | —— | —— | —— | ||
| $1.5M-20.0% | $1.88M+7.3% | $1.75M-1.9% | $1.78M+11.6% | $1.6M-17.4% | ||
| —— | —— | —— | —— | $105K+453% | ||
| —— | —— | —— | —— | $387K+252% | ||
| —— | —— | —— | —— | —— | ||
| -$553K-33.6% | -$414K-314% | -$100K+11.5% | -$113K+40.5% | -$190K+64.4% | ||
| -$1.92M-3.4% | -$1.86M-3.3% | -$1.8M-3.3% | -$1.74M-3.5% | -$1.68M-3.4% | ||
| -$10.25M+12.8% | -$11.75M+29.2% | -$16.58M-0.9% | -$16.43M+9.4% | -$18.14M+0.6% | ||
| -$10.25M+12.8% | -$11.75M+29.2% | -$16.58M-0.9% | -$16.43M+9.4% | -$18.14M+0.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Neuropace, Inc. generate?
- Neuropace, Inc. (NPCE) generated -$9.9M in operating cash flow over the trailing twelve months.
- What is Neuropace, Inc.'s free cash flow?
- After $412.0K of capital expenditures, Neuropace, Inc.'s free cash flow was -$10.2M over the trailing twelve months, up 43.5% year over year.
- Where does Neuropace, Inc.'s cash flow data come from?
- Every line is extracted from Neuropace, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
